top of page
Browse by category
Search
Could electro-acupuncture could help obesity management?
A team of scientists led by Nanyang Technological University Singapore (NTU Singapore) and Hong Kong University (HKU) has found evidence...
ASN issues guidance on the management of obesity in persons with kidney diseases
The American Society of Nephrology (ASN) has released its inaugural Kidney Health Guidance (KHG) on the Management of Obesity in Persons...
Semaglutide reduces COVID-19 related deaths in patients with obesity and CVD
Semaglutide reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established...
Surging US medical costs have employers taking a hard look at the return on investment
Only about half of US employers (52%) say they effectively manage healthcare costs, according to Gallagher's 2024 US Physical & Emotional...
Novel regulatory mechanism governing reactive oxygen species production associated with metabolic and immune pathway interactions in obesity
A novel regulatory mechanism governing reactive oxygen species (ROS) production in macrophages in response to energy overload, in which...
Semaglutide linked to uncommon blindness condition NAION
Patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye...
Specific gut bacteria are involved in compulsive eating and obesity
An international team of researchers has identified specific bacteria in the gut that are associated with both mice and humans developing...
Flagship Pioneering, ProFound Therapeutics and Pfizer to identify novel first-in-class therapeutics for the treatment of obesity
Flagship Pioneering and ProFound Therapeutics have entered a collaboration to conduct foundational research to identify potential...
Palatin initiates study of bremelanotide for the treatment of obesity
Palatin Technologies has begun a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate...
GLP-1 medications for teens with type 2 diabetes and obesity frequently denied by insurance companies
Health insurance companies often deny coverage for GLP-1 receptor agonists (GLP1Ra) that treat children and teens with obesity and type 2...
Browse by tag
bottom of page